AR012876A1 - Utilizacion de las heparinas de bajo peso molecular para la preparacion de medicamentos para la prevencion y el tratamiento del trauma del sistemanervioso central - Google Patents
Utilizacion de las heparinas de bajo peso molecular para la preparacion de medicamentos para la prevencion y el tratamiento del trauma del sistemanervioso centralInfo
- Publication number
- AR012876A1 AR012876A1 ARP980102470A ARP980102470A AR012876A1 AR 012876 A1 AR012876 A1 AR 012876A1 AR P980102470 A ARP980102470 A AR P980102470A AR P980102470 A ARP980102470 A AR P980102470A AR 012876 A1 AR012876 A1 AR 012876A1
- Authority
- AR
- Argentina
- Prior art keywords
- molecular weight
- trauma
- heparin
- low molecular
- prevention
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Utilizacion de heparinas de bajo peso molecular para la preparacion de medicamentos para la prevencion y el tratamiento del trauma del sistemanervioso central y, principalmente, del traumatismo espinal, craneal o cráneo- espinal. La heparina patron es un polisacárido sulfatado de peso molecularmedio de 12000-15000 daltons, aislado de las mucosas intestinales de la vaca, del cordero y del cerdo. La heparina es utilizada en clínica para la prevenciony el tratamiento de los desordenes tromboembolicos pero a veces provoca hemorragias. Desde hace una década, la heparina se ha reemplazado,progresivamente, por las heparinas de bajo peso molecular, que no presentan ya el inconveniente de hacer sangrar, o unicamente lo hacen en un grado menor, yque ya no necesitan mas que una inyeccion por día, en lugar de 2 a 3 inyecciones por día en el caso de la heparina patron. Los traumatismos delsistema nervioso central afectan al trauma del cerebro (trauma cerebral) y los traumas de la médula espinal (trauma medular). Las consecuencias de estostraumas son desordenes neurologicos tales como epilepsia, alteracion de la consciencia, problemas motores, amnesia, agresividad y déficit psicoafectivo.Se prefiere el uso deuna heparina de bajo peso molecular que tenga un peso molecular medio comprendido entre 1000 y 10000 daltons, principalmente entre1500 y 6000 daltons y, en particular, entre 4000 y 5000 daltons. Preferentemente, las heparinas de bajo peso molecular están constituidas poroligosacáridos que tienen u ácido2-O-sulfo-4-enopiranosuronico en una de sus extremidades. Se obtiene una heparina de bajo peso molecular particularmenteventajosa por depolimerizado de un éster de la heparina por medio de una base tal como la sosa.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9706550A FR2763848B1 (fr) | 1997-05-28 | 1997-05-28 | Utilisation des heparines de bas poids moleculaire pour la prevention et le traitement du trauma du systeme nerveux central |
Publications (1)
Publication Number | Publication Date |
---|---|
AR012876A1 true AR012876A1 (es) | 2000-11-22 |
Family
ID=9507335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP980102470A AR012876A1 (es) | 1997-05-28 | 1998-05-27 | Utilizacion de las heparinas de bajo peso molecular para la preparacion de medicamentos para la prevencion y el tratamiento del trauma del sistemanervioso central |
Country Status (24)
Country | Link |
---|---|
US (1) | US6380173B1 (es) |
EP (2) | EP0984786B1 (es) |
JP (1) | JP2002500660A (es) |
KR (1) | KR100531721B1 (es) |
CN (1) | CN1212845C (es) |
AR (1) | AR012876A1 (es) |
AT (1) | ATE276752T1 (es) |
AU (1) | AU752322B2 (es) |
BR (1) | BR9809504A (es) |
CA (1) | CA2290675A1 (es) |
DE (1) | DE69826460T2 (es) |
ES (1) | ES2227841T3 (es) |
FR (1) | FR2763848B1 (es) |
IL (2) | IL132671A0 (es) |
MA (1) | MA24553A1 (es) |
NO (1) | NO317517B1 (es) |
NZ (1) | NZ501365A (es) |
PE (1) | PE74699A1 (es) |
PT (1) | PT984786E (es) |
RU (1) | RU2215531C2 (es) |
TN (1) | TNSN98071A1 (es) |
TW (1) | TW533075B (es) |
WO (1) | WO1998053833A1 (es) |
ZA (1) | ZA984432B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010041686A1 (en) * | 2000-01-06 | 2001-11-15 | Veronique Mary | Novel therapeutic application of enoxaparin |
ITMI20012599A1 (it) * | 2001-12-11 | 2003-06-11 | Cosmo Spa | Composizioni farmaceutiche per la somministrazione orale di eparina osuoi derivati, utili per la terapia di malattie infiammatorie dell'int |
US9308220B2 (en) | 2001-12-11 | 2016-04-12 | Cosmo Technologies Limited | Pharmaceutical compositions for the oral administration of heparin or derivatives thereof |
US7511026B2 (en) | 2003-03-25 | 2009-03-31 | Seikagaku Corporation | Therapeutic agent for nerve damage |
ITMI20031023A1 (it) * | 2003-05-21 | 2004-11-22 | Umberto Cornelli | Glicosaminoglicani aventi peso molecolare medio 2400 d atti al trattamento delle disfunzioni emozionali. |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA829463B (en) * | 1982-07-19 | 1983-10-26 | Hepar Ind Inc | Process for manufacturing low molecular weight heparins by depolymerization of normal heparin |
FR2614026B1 (fr) * | 1987-04-16 | 1992-04-17 | Sanofi Sa | Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques |
IT1243300B (it) * | 1990-12-20 | 1994-05-26 | Fidia Spa | Derivati dell'eparina |
IT1264530B (it) * | 1992-07-31 | 1996-10-02 | Crinos Industria Farmaco | Impiego dei polisaccaridi nelle neuropatie atrofico degenerative |
-
1997
- 1997-05-28 FR FR9706550A patent/FR2763848B1/fr not_active Expired - Fee Related
-
1998
- 1998-05-19 PE PE1998000386A patent/PE74699A1/es not_active Application Discontinuation
- 1998-05-25 JP JP50031099A patent/JP2002500660A/ja not_active Ceased
- 1998-05-25 AU AU77759/98A patent/AU752322B2/en not_active Ceased
- 1998-05-25 TW TW087108065A patent/TW533075B/zh not_active IP Right Cessation
- 1998-05-25 DE DE69826460T patent/DE69826460T2/de not_active Expired - Lifetime
- 1998-05-25 RU RU99128105/14A patent/RU2215531C2/ru not_active IP Right Cessation
- 1998-05-25 MA MA25088A patent/MA24553A1/fr unknown
- 1998-05-25 ZA ZA984432A patent/ZA984432B/xx unknown
- 1998-05-25 KR KR10-1999-7010960A patent/KR100531721B1/ko not_active IP Right Cessation
- 1998-05-25 EP EP98925773A patent/EP0984786B1/fr not_active Expired - Lifetime
- 1998-05-25 CA CA002290675A patent/CA2290675A1/fr not_active Abandoned
- 1998-05-25 EP EP04003133A patent/EP1421943A1/fr not_active Withdrawn
- 1998-05-25 ES ES98925773T patent/ES2227841T3/es not_active Expired - Lifetime
- 1998-05-25 IL IL13267198A patent/IL132671A0/xx active IP Right Grant
- 1998-05-25 WO PCT/FR1998/001034 patent/WO1998053833A1/fr active IP Right Grant
- 1998-05-25 PT PT98925773T patent/PT984786E/pt unknown
- 1998-05-25 NZ NZ501365A patent/NZ501365A/xx unknown
- 1998-05-25 AT AT98925773T patent/ATE276752T1/de not_active IP Right Cessation
- 1998-05-25 BR BR9809504-8A patent/BR9809504A/pt not_active Application Discontinuation
- 1998-05-25 CN CNB988054892A patent/CN1212845C/zh not_active Expired - Fee Related
- 1998-05-27 AR ARP980102470A patent/AR012876A1/es unknown
- 1998-05-27 TN TNTNSN98071A patent/TNSN98071A1/fr unknown
-
1999
- 1999-11-01 IL IL132671A patent/IL132671A/en not_active IP Right Cessation
- 1999-11-12 NO NO19995538A patent/NO317517B1/no not_active IP Right Cessation
- 1999-11-24 US US09/448,244 patent/US6380173B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
PT984786E (pt) | 2005-01-31 |
AU752322B2 (en) | 2002-09-19 |
PE74699A1 (es) | 1999-10-21 |
EP0984786A1 (fr) | 2000-03-15 |
ATE276752T1 (de) | 2004-10-15 |
IL132671A (en) | 2007-06-17 |
BR9809504A (pt) | 2000-06-20 |
RU2215531C2 (ru) | 2003-11-10 |
IL132671A0 (en) | 2001-03-19 |
KR100531721B1 (ko) | 2005-11-28 |
FR2763848B1 (fr) | 2000-01-28 |
CN1212845C (zh) | 2005-08-03 |
NZ501365A (en) | 2002-12-20 |
ZA984432B (en) | 1998-12-02 |
TNSN98071A1 (fr) | 2005-03-15 |
NO995538L (no) | 1999-11-12 |
NO317517B1 (no) | 2004-11-08 |
AU7775998A (en) | 1998-12-30 |
CN1257428A (zh) | 2000-06-21 |
EP1421943A1 (fr) | 2004-05-26 |
ES2227841T3 (es) | 2005-04-01 |
WO1998053833A1 (fr) | 1998-12-03 |
EP0984786B1 (fr) | 2004-09-22 |
DE69826460T2 (de) | 2005-10-13 |
FR2763848A1 (fr) | 1998-12-04 |
CA2290675A1 (fr) | 1998-12-03 |
KR20010012988A (ko) | 2001-02-26 |
US6380173B1 (en) | 2002-04-30 |
MA24553A1 (fr) | 1998-12-31 |
NO995538D0 (no) | 1999-11-12 |
DE69826460D1 (de) | 2004-10-28 |
JP2002500660A (ja) | 2002-01-08 |
TW533075B (en) | 2003-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10493006B2 (en) | Injectable sterile aqueous formulation based on crosslinked hyaluronic acid and hydroxyapatite for aesthetic use | |
ES2647227T3 (es) | Método para reticular ácido hialurónico; método para preparar un hidrogel inyectable; hidrogel obtenido; uso del gel obtenido | |
AR014062A1 (es) | COMPOSICION DE METILFENIDATO PARA APLICACIoN TOPICA Y METODO PARA SU PREPARACION | |
BRPI0409890A (pt) | processo para a produção de um gel de polissacarìdeo reticulado, gel de polissacarìdeo reticulado substancialmente resistente à degradação de hialuronidase, composição farmacêutica, método para o tratamento ou a prevenção de um distúrbio ou uma condição selecionada do grupo que consiste em aumento de tecido, artrite, aderências de tecidos, capacidade imunogênica, doenças da mucosa, condições dermatológicas, condições oftalmológicas, condições hormonais, condições de lubrificação das juntas e condições cosméticas, em um indivìduo com necessidade do mesmo e uso de um gel | |
AU2020207813B2 (en) | Implants for sculpting, augmenting or correcting facial features such as the chin | |
BR112013026032A2 (pt) | composições nutricionais incluindo ácidos graxos de cadeia ramificada para cicatrização de ferida | |
SV2001000188A (es) | Aminoacidos biciclicos como agentes farmaceuticos | |
CA3209175A1 (en) | Hyaluronic acid-based gels including anesthetic agents | |
AR012876A1 (es) | Utilizacion de las heparinas de bajo peso molecular para la preparacion de medicamentos para la prevencion y el tratamiento del trauma del sistemanervioso central | |
ES2732317T3 (es) | Material de relleno dermocosmético y usos del mismo para fines estéticos | |
KR102320153B1 (ko) | 이중 가교를 통한 히알루론산 겔 및 이의 제조방법 | |
DE69923998T2 (de) | Verwendung eines neurologischen wirkstoffes zur herstellung eines medikamentes zur behandlung von erkrankungen des zentralen nervensystems | |
ES2660847T3 (es) | Ésteres fórmicos butíricos mezclados de polisacáridos ácidos, y su preparación y uso como cosméticos para la piel | |
US20190269597A1 (en) | Hyaluronic acid dermal fillers crosslinked with citric acid, method for making same and uses thereof | |
KR20170113660A (ko) | 피부 외관을 개선시키기 위한 조성물 및 방법 | |
ES2765001T3 (es) | Derivados silílicos de polisacáridos | |
US11324672B2 (en) | Method for preparing hyaluronic acid dermal fillers, dermal fillers obtained thereby and their use | |
AR055654A1 (es) | Tratamiento de trastornos neurodegenerativos | |
CN111315813A (zh) | 基于交联的糖胺聚糖的可吸收可植入装置及其制备方法 | |
EP3883618A1 (en) | Injectable composition including hyaluronic acid and use of the said composition | |
AR013347A1 (es) | Utilizacion de las heparinas de bajo peso molecular para la preparacion de medicamentos para la prevencion y el tratamiento de los edemas cerebrales | |
US10836840B2 (en) | Method for producing crosslinked hyaluronic acid | |
ES2850577T3 (es) | Conjugado de ácido hialurónico | |
ES2129999T3 (es) | Composicion gelificada estable con elevado contenido en electrolito. | |
EP2090308A1 (en) | Pharmaceutical composition for the treatment or prevention of osteoarticular diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |